International Journal of Molecular Sciences (May 2019)

Somatostatin and the “Small-For-Size” Liver

  • Amelia J. Hessheimer,
  • Lilia Martínez de la Maza,
  • Farah Adel Al Shwely,
  • Arlena Sofía Espinoza,
  • Fabio Ausania,
  • Constantino Fondevila

DOI
https://doi.org/10.3390/ijms20102512
Journal volume & issue
Vol. 20, no. 10
p. 2512

Abstract

Read online

“Small-for-size” livers arising in the context of liver resection and transplantation are vulnerable to the effects of increased portal flow in the immediate postoperative period. Increased portal flow is an essential stimulus for liver regeneration. If the rise in flow and stimulus for regeneration are excessive; however, liver failure and patient death may result. Somatostatin is an endogenous peptide hormone that may be administered exogenously to not only reduce portal blood flow but also offer direct protection to different cells in the liver. In this review article, we describe key changes that transpire in the liver following a relative size reduction occurring in the context of resection and transplantation and the largely beneficial effects that peri-operative somatostatin therapy may help achieve in this setting.

Keywords